Kaplan Fox Encourages Investors of Endava plc (NYSE: DAVA) to Contact the Firm Before Lead Plaintiff Deadline on November 30, 2026

A class action complaint alleges Endava misled investors during September 4, 2025–September 21, 2026, about its accounting treatment of certain customer and supplier agreements. Endava disclosed after the market close on September 21, 2026, that CFO Mark Thurston was on administrative leave amid an internal investigation into those accounting concerns; its ADSs fell $0.68, or over 24%, to $2.11 on September 22. Investors have until November 30, 2026, to seek appointment as lead plaintiff.

Analysis

The lawsuit itself is not the main risk: the disclosed internal investigation is. If the agreements under review affect revenue recognition, gross-versus-net presentation, or supplier cost timing, the issue could reach beyond a one-time legal expense into reported growth, margins, cash conversion, and the reliability of prior guidance. Those are conditional exposures, not established findings; the complaint’s allegations are unproven. The CFO’s administrative leave raises governance and control concerns, but does not by itself establish misconduct or a company-wide accounting failure.

Near term (days to 1–3 months), the key catalysts are investigation updates, auditor involvement, filing delays, and any restatement or guidance change. The November 30 lead-plaintiff deadline is procedural and should matter less than verified financial disclosures. Over 6–18 months, a confirmed accounting issue could increase customer diligence and procurement friction, potentially benefiting larger IT-services providers able to offer perceived execution and controls stability; any share shift is speculative absent customer evidence.

The prior 24% gap lower may already price substantial uncertainty, so a fresh outright short is unattractive without the current share price, borrow cost, liquidity, and balance-sheet data. Conversely, the low price alone is not evidence of cheapness: unresolved reporting risk can impair valuation and access to capital. Verify the agreements’ scope, cash-versus-reported revenue, auditor status, debt/covenant headroom, and listing compliance before taking directional exposure.

Key Decisions for Investors

• Keep DAVA on a high-risk watchlist; do not treat the lawsuit announcement as proof of accounting misconduct or as a standalone short signal.
• For existing exposure, size to the possibility of delayed filings or a restatement; reassess promptly if Endava identifies affected periods, revises results or guidance, or reports auditor concerns.
• Avoid adding on a price-based valuation thesis until the company clarifies the agreements under review and investors can reconcile reported revenue with cash collection and working capital.
• A tactical short is only a conditional setup after confirming current liquidity and borrow economics; falsify it if the investigation finds no material reporting issue and filings proceed without revision.